secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K/A
Filed at:   2026-05-11T21:30:26+00:00
Accession:  0001731122-26-000705
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Lunai Bioworks gets additional Nasdaq delisting notice for MVLS; completes $20M merger
--------------------------------------------------------------------------------

- Received Nasdaq staff determination on April 28, 2026 for non-compliance with $35M market value of listed securities (MVLS) rule.
- Completed merger on May 1, 2026, issuing $20M Series B Preferred Stock to support compliance with equity rule.
- Stockholders on May 8, 2026 approved reverse stock split authorization (1:3 to 1:30) to address bid price rule.
- Company requests extension from Nasdaq Hearings Panel for bid price compliance; prior exception expires June 1, 2026.
- Panel previously granted continued listing exception through May 1 (equity) and June 1 (bid price) subject to conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226000705/0001731122-26-000705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226000705/e7629_8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-000705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer